Abstract
AimsIn recent years, genomic technologies have enabled the identification of mutations in acute myeloid leukaemia (AML). DNMT3A is a recurrently mutated epigenetic modifier gene in AML. To date, the prognostic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have